Clinical Trials at Health Partners Inc
As of August 2026, 37 paid clinical trials are recruiting at Health Partners Inc, located at 1929 S 5TH ST STE 101, MINNEAPOLIS, MN 55454-1274, phone (651) 621-9033 in Minneapolis, Minnesota. Active studies at this site cover conditions such as Heart Failure, Acute Myeloid Leukemia and Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
37 clinical trials at Health Partners Inc
·Clear filters·Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Common conditions studied in Minneapolis
- Heart Failure (17 active studies)
- Acute Myeloid Leukemia (16 active studies)
- Ovarian Cancer (13 active studies)
- Breast Cancer (12 active studies)
- Coronary Artery Disease (11 active studies)
- Endometrial Cancer (11 active studies)
Leading research sponsors in Minneapolis
- University of Minnesota
- National Cancer Institute (NCI)
- Masonic Cancer Center, University of Minnesota
- VA Office of Research and Development
- Children's Oncology Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Minneapolis?
There are approximately 909 recruiting clinical trials in Minneapolis, Minnesota listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Minneapolis pay participants?
Most recruiting trials in Minneapolis compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Minneapolis?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Minneapolis?
The most common conditions under active study in Minneapolis include Heart Failure (17), Acute Myeloid Leukemia (16), Ovarian Cancer (13), Breast Cancer (12), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Minneapolis?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Minneapolis on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Minneapolis?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Minneapolis?
Recruiting research sites in Minneapolis include University of Minnesota, Abbott-Northwestern Hospital, Hennepin County Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Minneapolis right now?
The largest active categories in Minneapolis are Cancer & tumors (246), Cardiovascular (72), Neurology & pain (54). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Health Partners Inc?
Health Partners Inc is located at 1929 S 5TH ST STE 101, MINNEAPOLIS, MN 55454-1274. Use the Google Maps link in the intro above to get directions.
How do I contact Health Partners Inc?
You can reach Health Partners Inc by phone at (651) 621-9033. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.